Crohn'
Conditions
Interventions
5 ml of blood sample and 3 biopsy samples of the intestinal tissue will be collected from each person.
Sponsors
Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with inflammatory bowel disease and healthy volunteers.
Exclusion criteria
Exclusion criteria: [Patients] Pregnant women are excluded. Patients who have obvious intestinal disease and/or systemic inflammation caused by other than inflammatory bowel disease, such as advanced cancer, systemic autoimmune disease, and infections are excluded. Patients with bleeding tendency are excluded. [Healthy volunteers] Pregnant women are excluded. Persons with bleeding tendency are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The immunological profiling will be determined by the measurement of cytokines, chemokines and other factors in the serum and intestinal tissue samples. The patients will be classified into subgroups by the immunological features, and the correlation of endoscopical disease activity, clinical course, and the responsiveness and/or resistance to therapy protocol with those subgroups will be analyzed. | — |
Secondary
| Measure | Time frame |
|---|---|
| The feasibility of immunological profiling for the selection of proper therapeutic strategy and prediction of the clinical course. | — |
Countries
Japan
Contacts
Public ContactNamiko Hoshi
Kobe University Graduate School of Medicine Gastroenterology
Outcome results
None listed